Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view

Area of Science:

• Molecular biology
• Cancer research
• Structural biology

Background:

• Ras proteins are key regulators of cell signaling, controlling growth and proliferation.
• Activating Ras mutations are implicated in ~30% of human cancers and often confer resistance to therapies.
• Emerging drug resistance necessitates understanding parallel signaling pathways.

Purpose of the Study:

• To review advances in Ras structural biology and therapeutic inhibition strategies.
• To propose co-targeting strategies to overcome drug resistance in Ras-driven cancers.
• To provide a comprehensive plan for tackling mutant Ras proteins.

Main Methods:

• Overview of current structural knowledge of Ras proteins, including dynamics and interactions.
• Analysis of therapeutic strategies targeting Ras active sites, allosteric sites, and protein-protein interfaces.
• Identification and rationale for co-targeting pathways like YAP1, c-Myc, MAPK/ERK, and PI3K/Akt/mTOR.

Main Results:

• Advances in structural biology enable the development of Ras inhibitors.
• Targeting Ras directly, including dimers and complexes like K-Ras4B/calmodulin/PI3Kα, shows promise.
• Co-targeting YAP1 and c-Myc pathways alongside Ras signaling is proposed to mitigate resistance.

Conclusions:

• Structural insights are crucial for developing novel Ras inhibitors for cancer treatment.
• Understanding resistance mechanisms is key to designing effective, durable therapies.
• A combined strategy of direct Ras inhibition and co-targeting of parallel pathways offers a promising approach for RAS-driven cancers.